Nordwand Advisors LLC lessened its stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 89.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 312,155 shares of the medical equipment provider's stock after selling 2,717,669 shares during the period. NovoCure comprises about 3.8% of Nordwand Advisors LLC's holdings, making the stock its 3rd biggest position. Nordwand Advisors LLC owned about 0.29% of NovoCure worth $9,302,000 as of its most recent filing with the SEC.
Several other hedge funds have also added to or reduced their stakes in the stock. Los Angeles Capital Management LLC purchased a new stake in NovoCure in the third quarter worth $239,000. Venturi Wealth Management LLC grew its stake in shares of NovoCure by 58.5% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,669 shares of the medical equipment provider's stock worth $57,000 after acquiring an additional 1,354 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in NovoCure by 16.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 426,263 shares of the medical equipment provider's stock worth $6,662,000 after acquiring an additional 59,608 shares during the last quarter. Intech Investment Management LLC bought a new stake in NovoCure in the 3rd quarter valued at about $346,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in NovoCure by 2.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 824,443 shares of the medical equipment provider's stock valued at $12,886,000 after purchasing an additional 16,339 shares during the last quarter. Institutional investors own 84.61% of the company's stock.
NovoCure Price Performance
Shares of NASDAQ:NVCR traded up $1.03 on Tuesday, hitting $21.32. The company's stock had a trading volume of 1,244,699 shares, compared to its average volume of 1,253,118. The company has a market capitalization of $2.34 billion, a PE ratio of -15.23 and a beta of 0.63. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.49 and a quick ratio of 1.44. The company has a 50-day simple moving average of $24.18 and a 200 day simple moving average of $21.52. NovoCure Limited has a 1 year low of $11.70 and a 1 year high of $34.13.
NovoCure (NASDAQ:NVCR - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.27). NovoCure had a negative net margin of 25.93% and a negative return on equity of 41.48%. The company had revenue of $161.27 million during the quarter, compared to analysts' expectations of $161.30 million. Sell-side analysts forecast that NovoCure Limited will post -1.3 EPS for the current fiscal year.
Analyst Ratings Changes
NVCR has been the topic of a number of recent research reports. Evercore ISI upgraded shares of NovoCure from an "in-line" rating to an "outperform" rating and upped their price target for the company from $18.00 to $30.00 in a research note on Monday, December 2nd. Wedbush reaffirmed a "neutral" rating and issued a $29.00 price target on shares of NovoCure in a report on Monday, January 13th. HC Wainwright reiterated a "buy" rating and set a $38.00 price objective on shares of NovoCure in a research note on Tuesday, January 14th. Piper Sandler raised their target price on NovoCure from $28.00 to $42.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. Finally, StockNews.com lowered NovoCure from a "hold" rating to a "sell" rating in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $32.67.
Read Our Latest Report on NVCR
NovoCure Company Profile
(
Free Report)
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.
Featured Stories
Before you consider NovoCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NovoCure wasn't on the list.
While NovoCure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
